Recovery Legal Care Clinical Trial
NCT06618794
Recruiting
Hospital-Based Violence Intervention Programs (HVIPs) affiliated with trauma centers in the US often focus on individual behavior modification for reduction in re-victimization. There is a lack of reproducible evidence that has demonstrated effectiveness, given the exclusion of addressing inequities in the Social and Structural Determinants of Health (SSDOH), often the root causes of violent injury and preventable homicide. The study investigators created a Medical Legal Partnership (MLP) to par... Read More
Gender:
ALL
Ages:
Between 14 years and 64 years
Trial Updated:
07/01/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Firearm Injury, Economic Problems, Injury Traumatic, Racism, Systemic
Register for Updates
mHealth Behavior Study
NCT06624514
Recruiting
The goal of this clinical trial is to learn if a brief task completed on a smartphone can reduce alcohol use and risky sexual behavior among women between the ages of 18 and 25 who have a history of experiencing sexual assault or an unwanted sexual experience. The main questions it aims to answer are: * Does the smartphone task change approach biases for alcohol and condom-related images? * Does the smartphone task reduce alcohol use and risky sexual behavior? Researchers will compare the smar... Read More
Gender:
FEMALE
Ages:
Between 18 years and 25 years
Trial Updated:
07/01/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Alcohol Consumption, Condom Use
Register for Updates
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
NCT06627335
Recruiting
This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.
Gender:
FEMALE
Ages:
14 years and above
Trial Updated:
07/01/2025
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Register for Updates
MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT06648434
Recruiting
The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Cancer of the Pancreas
Register for Updates
Intensive Longitudinal Assessment of Stress and Stress-related Concepts Across a Behavioral Weight Loss Intervention
NCT06668259
Recruiting
Examine the association between variability in individual stress and related concepts with weight loss, physical activity, and sleep across a behavioral weight loss program
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Fairway North, Fairway, Kansas +1 locations
Conditions: Individual Stress and Weight Loss
Register for Updates
Sleep Treatment Education Program for Cancer Survivors: STEP-Together
NCT06736548
Recruiting
This single-arm research study of off-treatment cancer survivors with self-reported symptoms of insomnia will test the Sleep Treatment Education Program Together (STEP-Together) intervention which is delivered as a synchronous group session by videoconference.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/01/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Insomnia, Insomnia Chronic, Survivorship
Register for Updates
A Single-center Study of Setmelanotide in Patients With Prader-Willi Syndrome
NCT06772597
Recruiting
This is a Phase 2, single-center, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 26 weeks.
Gender:
ALL
Ages:
Between 6 years and 65 years
Trial Updated:
07/01/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Prader-Willi Syndrome, Obesity, Hyperphagia
Register for Updates
A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
NCT06774313
Recruiting
This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/01/2025
Locations: Acpru /Id# 271899, Grayslake, Illinois
Conditions: Healthy Volunteer
Register for Updates
Loncastuximab Tesirine and Rituximab as Bridging Therapy Prior to Standard-of-care CD19 CAR T-cell Therapy in Patients With Large B-cell Lymphoma
NCT06788964
Recruiting
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah
Conditions: Relapsed or Refractory Large B-cell Lymphoma
Register for Updates
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Scottsdale, Arizona +74 locations
Conditions: Metastatic Colorectal Cancer
Register for Updates
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
NCT06797518
Recruiting
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease pro... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/01/2025
Locations: Nephronet Clinical, Buford, Georgia +3 locations
Conditions: Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
Register for Updates
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
NCT06804603
Recruiting
The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2025
Locations: Vanda Investigational Site, Los Angeles, California +2 locations
Conditions: Obesity
Register for Updates